<DOC>
	<DOCNO>NCT01123161</DOCNO>
	<brief_summary>The purpose trial determine whether combination thrombolysis hypothermia superior thrombolysis alone treatment acute ischemic stroke .</brief_summary>
	<brief_title>The Intravascular Cooling Treatment Stroke 2/3 Trial</brief_title>
	<detailed_description>A stroke usually cause blockage one arteries carry blood brain . Research show tissue plasminogen activator ( tPA ) —a naturally occur protein open blocked artery dissolve blood clot — activate body 's ability dissolve recently form blood clot reduce prevents brain damage cause stroke . The Food Drug Administration ( FDA ) approve use tPA people stroke take within 3 hour stroke onset . Researchers believe low body temperature ( hypothermia ) may beneficial stroke happen hypothermia may prevent brain injury , may make stroke less damaging . Patients receive standard stroke evaluation , include blood test , compute tomography ( CT ) scan , complete physical neurological examination , electrocardiogram ( EKG ) determine eligibility study . There two study group - tPA alone tPA cooling ( hypothermia ) . Participants randomly assign one two study group . Length participation ( include observation patient leave hospital ) 90 day . This study part Specialized Program Translational Research Acute Stroke ( SPOTRIAS ) , allow researcher enhance initiate translational research ultimately benefit stroke patient treat patient le 2 hour , find way treat additional patient later .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>1 . Age 22 82 year old inclusive 2 . Patient receive IV rtPA use standard guideline 3 . NIHSS score ≥ 7 ≤ 20 ( right hemisphere ) ≥ 7 ≤ 24 ( leave hemisphere ) time randomization 4 . Prestroke mRS 01 5 . Able begin endovascular phase hypothermia within 2 hour tPA completion 6 . Written Informed Consent , sign date patient ( patient 's authorized representative ) 1 . Etiology ischemic stroke 2 . Item 1a NIHSS &gt; 1 time randomization 3 . Clinical symptom consistent brainstem cerebellar stroke 4 . Classic lacunar syndrome image confirmation small deep ischemia , randomization delay neuroimaging initial scan exclude hemorrhage 5 . Known contraindication hypothermia , know hematologic dyscrasia affect thrombosis ( cryoglobulinemia , Sickle cell disease , serum cold agglutinin ) , vasospastic disorder Raynaud 's thromboangiitis obliterans 6 . Known comorbid condition likely complicate therapy opinion investigator , e.g. , . Heart failure ( NYHA class III IV ) * ii . Uncompensated arrhythmia iii . Severe Liver disease iv . History pelvic abdominal mass likely compress inferior vena cava v. IVC filter vi . HIV positive vii . Clinically active hypo hyperthyroidism viii . Renal insufficiency likely impair meperidine clearance ix . Chronic ethanol abuse x . History HIT ( heparin induce thrombocytopenia ) 7 . Pregnancy ( All woman childbearing potential must negative pregnancy test , urine blood , prior therapy . ) 8 . Medical condition likely interfere patient assessment . 9 . Known allergy meperidine buspirone 10 . Currently take use within previous 14 day MAOI class medication . 11 . Life expectancy &lt; 6 month 12 . Not likely available longterm followup 13 . Use , plan use , intraarterial thrombolysis , mechanical clot removal , experimental approve acute therapy stroke event 14 . Chest radiograph clinical presentation suggestive pneumonia clinically significant pulmonary edema baseline . 15 . Temperature upon admission great equal 38°C</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>82 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hypothermia</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Cerebral Infarction</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Stroke</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Tissue Plasminogen Activator</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Fibrinolytic Agents</keyword>
	<keyword>Cardiovascular Agents</keyword>
	<keyword>Body Temperature Changes</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Cerebrovascular Disorders</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Signs Symptoms</keyword>
	<keyword>Fibrin Modulating Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Brain Ischemia</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Brain Infarction</keyword>
	<keyword>Plasminogen</keyword>
	<keyword>cool</keyword>
	<keyword>tPA</keyword>
	<keyword>thrombolysis</keyword>
</DOC>